IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market. The offering supports clients’ critical commercial applications through comprehensive coverage of the specialty pharmacy provider channel, coupled with IMS’s extensive anonymized patient-centered insights.

“This marks a significant advance for our clients that offer specialty medications, all of whom share a vital interest in a market segment that’s growing at twice the pace of traditional pharmaceutical products,” said Pam Sauerwald, general manager, Specialty Offerings Development, IMS. “As demand for evidence-based information in the specialty sector grows, we’re uniquely positioned to provide a deeper understanding into how these products are used – helping clients to adjust portfolio strategies and improve their commercial effectiveness.”

The IMS offering provides unprecedented insights into channel dynamics, with longitudinal information from the specialty pharmacy provider channel that can be applied in combination with retail and standard mail service channel assessments. This enables clients to identify trends and growth opportunities relating to utilization, product switching, compliance and persistence by channel, product usage by indication, common treatment regimens, and channel-to-channel dynamics.

Today, specialty pharmaceutical products dominate R&D pipelines, with global sales expected to exceed $160 billion by 2013. IMS Specialty Market Dynamics already is being used by several leading pharmaceutical companies that offer treatments in key specialty therapeutic areas, including autoimmune biologics and oral oncology.

IMS Specialty Market Dynamics is the latest addition to IMS Specialty SolutionsTM, the company’s portfolio of next-generation market intelligence products and consulting services focused exclusively on specialty markets. Building on uniform information from more than 25 specialty pharmacy providers, IMS Specialty Solutions empowers clients to make evidence-based, commercial decisions faster and with greater efficiency.

Specialty Products Defined

IMS defines specialty products as a class of medications that are used to treat complex, chronic conditions that include cancer, Crohn’s Disease, growth hormone disorders, hemophilia, hepatitis C, HIV, infertility, multiple sclerosis, psoriasis, pulmonary arterial hypertension and rheumatoid arthritis, among others. Specialty products are typically produced through biotechnology and administered by injection, and/or require special patient monitoring and handling.

About IMS

Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.3 billion in 2008 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.

As a global leader in protecting individual patient privacy, IMS uses de-identified healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.

IMS Health (NYSE:RX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse IMS Health
IMS Health (NYSE:RX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse IMS Health